Ben Derman (@bdermanmd) ranks #8 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 26 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: MajesTEC-9, SUCCESSOR-2, RedirecTT-1. CMS Open Payments lists $37,106 in 2025 general payments.
At a Glance
- 5 posts naming a trial since ASH 2025
- 4 trials discussed by name
- Multiple Myeloma: US #8, Global #9 · 26 physicians engaged
- Leading physician voice: #2 of 15 physicians on SUCCESSOR-2; #2 of 10 physicians on RedirecTT-1
- CMS Open Payments lists $37,106 in 2025 general payments.
This Month
What Ben Derman has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
Who Amplifies Ben Derman
Physicians who reposted Ben Derman’s trial posts most often since ASH 2025.
- BK
Bhuvan Kishore3 reposts - TC
Tontarn Chutima3 reposts - MT
Mike Thompson, MD, PhD, FASCO2 reposts - DC
Dr. Chokri Ben Lamine2 reposts - RB
Rahul Banerjee, MD, FACP2 reposts - O
Olga1 repost - LB
Liz Brem, MD1 repost - YG
Yahya G. Hummadi1 repost - RF
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽1 repost - MB
Marc Braunstein, MD, PhD, FACP, FASCO1 repost
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #8 | #9 | 67/100 | 26 | 36 | Full ranking |
What Colleagues Are Saying About Ben Derman
2026 posts by fellow physicians that mention @bdermanmd, quoted word for word.
#ASH25 #mmsm @ASH_hematology Treatment Refinement in Multiple Myeloma @bdermanmd Some studies implementing MRD strategies to stop therapy https://t.co/H0qQQpsvzW
Trials Ben Derman Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| MajesTEC-9 | 2 | #5 of 16 | May 29, 2026 |
| SUCCESSOR-2 | 2 | #2 of 15 | May 29, 2026 |
| RedirecTT-1 | 1 | #2 of 10 | Dec 7, 2025 |
| BENEFIT | 1 | — | Dec 6, 2025 |
Ben Derman on MajesTEC-9
We now have release of SUCCESSOR-2 data! Mezi + weekly Kd vs twice weekly Kd - 85% anti cd38 refractory - mPFS 18 vs 8 months (control arm did the same as MajesTEC-9) My take: 18 months is nothing to scoff at, and compares favorably with KPd data. It still leaves something to be https://t.co/3ZcLf3f0Pa https://t.co/wQiEOcDK6z
1) MajesTEC-9 (Mina, 7507) - Teclistamab vs. (VPd or Kd). Full summary below. Tec clearly beats out some inferior and less-than-standard comparators. I want to make 4 points about this study 1 - VPd and Kd are not strong comparators, but outside of CAR T/BsAb, there are not https://t.co/ELu6cD9khQ
Ben Derman on SUCCESSOR-2
We now have release of SUCCESSOR-2 data! Mezi + weekly Kd vs twice weekly Kd - 85% anti cd38 refractory - mPFS 18 vs 8 months (control arm did the same as MajesTEC-9) My take: 18 months is nothing to scoff at, and compares favorably with KPd data. It still leaves something to be https://t.co/3ZcLf3f0Pa https://t.co/wQiEOcDK6z
3) SUCCESSOR-2. Mezi-Kd vs. Kd. It's a late breaker so stay tuned for the data. This will be an important study as it will serve as the FIRST randomized study of carfilzomib with an IMiD/CELMoD. This could help to establish an effective regimen for anti-CD38 refractory patients
Ben Derman on RedirecTT-1
A simultaneous presentation and NEJM publication for ReDirecTT-1: Tec + Tal in EMD by @szusmani n=90; ORR 79% 12-month PFS 57.5% Grade 3+ infections 32%. 8 discontinuations due to AEs. 10 AE-related deaths. Overall, amazing to have a dedicated EMD study. This is truly a https://t.co/MtyyykgQ8u
Ben Derman on BENEFIT
Re: sustained MRD negativity in BENEFIT. It is notable that despite longer courses of bortezomib than CEPHEUS, the sustained MRD negativity is generally low for quad therapy despite relatively high dose intensity. Another interesting observation is that patients with t(11;14) https://t.co/8FkwZ5FA3i
Ben Derman’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
The main change for this cycle: "Ciltacabtagene autoleucel or the combination of teclistamab and daratumumab are preferred options at first relapse in eligible patients who have not previously received B-cell maturation antigen (BCMA) directed therapy. Teclistimatab plus
Working on this study was truly a labor of love! Durca-cel is a BCMA-directed CAR T that was manufactured exceedingly quickly, and this phase I study came at a time when we had very limited slot availability for commercial CAR T. While the PFS was ‘only’ 12 months, we were able
Industry Payments
CMS Open Payments · 2025 general payments
$37,106 across 30 payments